GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » EBIT

Integra Lifesciences Holdings (Integra Lifesciences Holdings) EBIT : $99 Mil (TTM As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings EBIT?

Integra Lifesciences Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Integra Lifesciences Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was 0.30%. Integra Lifesciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.68%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Integra Lifesciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.22%.


Integra Lifesciences Holdings EBIT Historical Data

The historical data trend for Integra Lifesciences Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings EBIT Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.06 165.10 265.07 263.49 132.45

Integra Lifesciences Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.88 16.29 31.67 42.61 8.39

Competitive Comparison of Integra Lifesciences Holdings's EBIT

For the Medical Devices subindustry, Integra Lifesciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's EV-to-EBIT falls into.



Integra Lifesciences Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings  (NAS:IART) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Integra Lifesciences Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=15.856 * ( 1 - 37.27% )/( (3279.722 + 3320.727)/ 2 )
=9.9464688/3300.2245
=0.30 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3781.988 - 193.17 - ( 309.096 - max(0, 306.98 - 1058.036+309.096))
=3279.722

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4078.224 - 94.397 - ( 663.1 - max(0, 302.394 - 1415.65+663.1))
=3320.727

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Integra Lifesciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=33.576/( ( (496.383 + max(471.775, 0)) + (0 + max(466.459, 0)) )/ 2 )
=33.576/( ( 968.158 + 466.459 )/ 2 )
=33.576/717.3085
=4.68 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(259.327 + 389.608 + 100.005) - (193.17 + 8.54 + 75.455)
=471.775

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(241.092 + 403.422 + 108.036) - (94.397 + 0 + 191.694)
=466.459

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Integra Lifesciences Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=98.962/1590.840
=6.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Executives
Chantal Veillon-berteloot officer: EVP & CHRO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook officer: SVP, Fin & PAO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight officer: EVP & CFO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz officer: Corp VP, Gen Counsel & Sec C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De director, officer: President & CEO C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen officer: Executive VP & President, CSS 1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh officer: Exec VP & PRES, International 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli officer: Chief Human Resources Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy director 14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman officer: CVP, CHIEF FINANCIAL OFFICER C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p. 10 percent owner 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini officer: President & COO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig director, officer: President and CEO 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Headlines

From GuruFocus